NutriBand (NTRB) Change in Receivables (2018 - 2026)
NutriBand (NTRB) posted Change in Receivables of -$115772.0 for Q2 2026, down 297.05% sequentially from -$29158.0 in Q1 2026, and down 670.61% YoY from $20289.0 in Q2 2025.
NutriBand (NTRB) Change in Receivables (2018 - 2026) Analysis & Trends
NutriBand has reported Change in Receivables for 9 years, with the latest figure at -$115772.0 in Q2 2026.
- Quarterly Change in Receivables fell 670.61% year-over-year to -$115772.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$91504.0 (down 1117.62% YoY) and the FY2026 annual result came in at $44557.0, up 159.57% from the prior year.
- Change in Receivables eased to -$115772.0 in Q2 2026 per NTRB's latest filing, from -$29158.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $85508.0 in Q1 2024 and troughed at -$115772.0 in Q2 2026.
- A 5-year average of -$1689.7 and a median of $3523.5 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables soared 489.12% in 2025, then plunged 670.61% in 2026.
- Over 5 years, Change in Receivables stood at -$66102.0 in 2022, then climbed by 18.64% to -$53783.0 in 2023, then soared by 177.38% to $41619.0 in 2024, then slumped by 131.82% to -$13242.0 in 2025, then slumped by 774.28% to -$115772.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$115772.0, -$29158.0, and -$13242.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 | -115,772.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -115,772.00 |
| Apr 30, 2026 | -115,772.00 |
| Jan 31, 2026 | -29,158.00 |
| Jan 31, 2026 | -29,158.00 |
| Oct 31, 2025 | -13,242.00 |
| Oct 31, 2025 | -13,242.00 |
| Jul 31, 2025 | 66,668.00 |
| Jul 31, 2025 | 66,668.00 |
| Apr 30, 2025 | 20,289.00 |
| Apr 30, 2025 | 20,289.00 |
| Jan 31, 2025 | -35,783.00 |
| Jan 31, 2025 | -35,783.00 |
| Oct 31, 2024 | 41,619.00 |
| Oct 31, 2024 | 41,619.00 |
| Jul 31, 2024 | -17,133.00 |
| Jul 31, 2024 | -17,133.00 |
| Apr 30, 2024 | -63,505.00 |
| Apr 30, 2024 | -63,505.00 |
| Jan 31, 2024 | 85,508.00 |
| Jan 31, 2024 | 85,508.00 |